Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DESTINATION long-term safety extension study of tezepelumab in adults with severe uncontrolled asthma
MOH_2019-03-31_006058Phase 3Not yet recruiting
- Sponsor
- AstraZeneca
- Start
- Mar 2019
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in asthma comparing Tezepelumab with Placebo (2 arms). Planned start Mar 2019; status: not yet recruiting.
02
Drugs
03
Conditions
asthma
Beyond the preview
Go deeper on MOH_2019-03-31_006058.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2019-03-31_006058.